|Articles|June 29, 2010
New Core Imaging Lab, Imaging Endpoints, Launches in Arizona
Advertisement
Imaging Endpoints
, a core medical imaging lab focused on accelerating the crucial clinical trial process for pharmaceutical and medical device manufacturers, has officially launched.
Pharmaceutical and medical device manufacturers understand that medical imaging plays an integral part in the clinical trial process by helping to validate which drugs and devices are demonstrating efficacy. By identifying what is referred to as “imaging endpoints” (the overall outcome the clinical trial protocol is designed to evaluate), these companies, with the support of a core imaging lab, can effectively obtain results and determine if those endpoints are met. Imaging Endpoints provides the efficacy support needed to garner FDA approval to introduce new products to the market with the intent of improving patient outcomes.
Imaging Endpoints sets out to expedite the clinical trial process and serves as a central hub for collection, processing, quality review and standardized radiologic analysis of medical images. Additionally, Imaging Endpoint radiologists serve as blind readers and provide medical image interpretation, a fundamental component of the core imaging lab business for clinical trial sponsors.
Imaging Endpoints specializes in oncologic, cardiovascular, neurological and musculoskeletal trials. Imaging Endpoints is comprised of a group of board-certified, fellowship-trained radiologists and project managers.
Imaging Endpoints’ project managers have experience in clinical trials within pharmaceutical and medical device companies, and its parent company has functioned as a clinical imaging site in numerous trials.
Pharmaceutical and medical device manufacturers understand that medical imaging plays an integral part in the clinical trial process by helping to validate which drugs and devices are demonstrating efficacy. By identifying what is referred to as “imaging endpoints” (the overall outcome the clinical trial protocol is designed to evaluate), these companies, with the support of a core imaging lab, can effectively obtain results and determine if those endpoints are met. Imaging Endpoints provides the efficacy support needed to garner FDA approval to introduce new products to the market with the intent of improving patient outcomes.
Imaging Endpoints sets out to expedite the clinical trial process and serves as a central hub for collection, processing, quality review and standardized radiologic analysis of medical images. Additionally, Imaging Endpoint radiologists serve as blind readers and provide medical image interpretation, a fundamental component of the core imaging lab business for clinical trial sponsors.
Imaging Endpoints specializes in oncologic, cardiovascular, neurological and musculoskeletal trials. Imaging Endpoints is comprised of a group of board-certified, fellowship-trained radiologists and project managers.
Imaging Endpoints’ project managers have experience in clinical trials within pharmaceutical and medical device companies, and its parent company has functioned as a clinical imaging site in numerous trials.
- Imaging Endpoints’ services include:
- Analyzing imaging data from a qualitative/quantitative perspective as appropriate
- Defining and developing imaging strategies and protocols
- Optimizing imaging endpoints
- Configuring site and independent image-review strategies
- Imaging site selection and qualification
- Independent review charter development
- Review of study and expert reports
- Regulatory submission support
- Mining of post-approval imaging data
Ronald Korn, MD, PhD, serves as Imaging Endpoints’ medical director.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
- Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV Patients
September 12th 2025
- Latest NIMBLE Study Results Highlight Progress in gMG Research
September 12th 2025
- ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug Trials
September 11th 2025
Advertisement
Advertisement